Opioid use disorder

Opioid use disorder emerges in the book as both a condition of dependence and a problem shaped by the systems meant to prevent, recognize, and treat it. Its modern reach cannot be separated from the expansion of opioid prescribing, the stigma that silenced families, and treatment pathways that could be expensive, interrupted, or socially rejected. The book places individual struggles within this larger history: what was presented as reliable pain care could expose patients to risk, while the institutions around them often struggled to provide sustained support.

Medicalization and the Expansion of Prescribing

The promotion of OxyContin drew authority from claims that addiction was exceptionally uncommon when the drug was used as prescribed. Purdue Pharma’s representative on pain, David Haddox, relayed a claimed risk of one-half of one percent; a company training described doctor-caused addiction as extraordinarily rare. These assurances framed opioid treatment as both dependable and responsible, helping normalize its use for pain beyond cancer, including injuries and other common conditions.

That promotion coincided with a change in how medicine assessed pain. In 1996, doctors, hospitals, and accreditation bodies were adopting pain as the fifth vital sign, to be assessed alongside blood pressure, heart rate, breathing rate, and temperature. When the Joint Commission adopted mandatory pain-assessment and treatment standards in 1999, the measurement of pain became a practical institutional priority. Patient-satisfaction surveys also influenced reimbursement, giving hospitals and clinicians reason to treat pain more aggressively.

The new standard appeared precise, but the underlying measure remained subjective. A pain score could make unlike experiences appear comparable, while a high score did not necessarily establish which treatment would improve a patient’s outcome. The book reports that reliance on pain scales did not correspond with better outcomes and was associated with increased opioid prescribing and abuse. Purdue recognized the institutional opening: its budget plan described an opportunity to position the company as a leader helping hospitals meet the new standards. The proposed materials included $300,000 in branded scroll pens, $225,000 in resource binders, and $290,000 in wall charts and clipboards bearing the fifth-vital-sign message.

The broader promotional climate reinforced that expansion. After federal rules for pharmaceutical advertising were loosened, spending on drug advertising rose from $360 million in 1995 to $1.3 billion in 1998, while drug companies increased their provision of gifts to doctors. In rural towns already marked by shuttered factories and rising disability claims, Purdue used prescribing data to direct sales representatives toward doctors who prescribed competing painkillers heavily. The result was not simply a new product entering a neutral medical landscape: commercial messages, clinical standards, and pressure to relieve pain helped widen the place of opioids in ordinary care.

Risk, Dependence, and the Limits of Treatment

The gap between reassurances about low risk and the experience of dependence is central to the book’s account. A short course or prescribed use did not guarantee that a person would remain unaffected. The narrative records a physician’s later recognition that he had once told residents that fourteen days of opioid pills could not lead to dependence, and that he had been wrong. The change in his understanding captures the limits of professional confidence during a period when prescribing was encouraged before its consequences were fully understood.

The book’s accounts also show how treatment could begin without establishing a durable course of care. Jesse Bolstridge entered a ten-week program in Jacksonville in January 2013 that included counseling and medical detoxification. He briefly received buprenorphine, a medication intended to reduce cravings, but was weaned from it after three weeks. His mother, Kristi Fernandez, still owed $25,000 for the earlier treatment, despite insurance coverage and weekly payments drawn automatically from Jesse’s checking account. National Institute on Drug Abuse director Nora Volkow argued that evidence supported long-term medication maintenance alongside behavioral treatment and recovery support, rather than short detoxification programs aimed at abstinence. The contrast makes the duration and continuity of care consequential, not incidental.

Access was also limited by pregnancy and facility policy. After leaving jail in June 2015, Tess Henry spent her final month of pregnancy at the Life Center of Galax, one of the few Virginia facilities that accepted patients receiving medication-assisted treatment. Private insurance covered most of the $20,000 cost; her father paid the $6,500 deductible from the remainder of her college savings. Tess had spent the first half of her pregnancy using heroin and the second half taking Subutex, a buprenorphine formulation then recommended for some pregnant patients. Her circumstances show how treatment depended not only on a medication’s clinical role but on whether a facility would accept a patient and whether a family could meet the cost.

Stigma, Families, and the Gaps Between Systems

Stigma shaped what families could say and when they could seek help. When reporting on the heroin epidemic in the suburbs of Roanoke, Virginia, began in 2012, many families were too ashamed to speak publicly. Five years later, as the book was completed, nearly everyone agreed to be named, though some still feared consequences for their jobs or safety. The change in willingness to be identified marks a shift in disclosure, not the disappearance of risk or shame.

The book describes families working in the gaps between health care and criminal justice. At a Families Anonymous meeting at a Lutheran church near Hidden Valley, two mothers of young men with opioid problems met; their chance encounter connected experiences that institutions often handled separately. The account emphasizes the daily stakes of those gaps: people with addiction tried to stay alive and avoid withdrawal, while relatives and volunteers tried to keep them alive. Shame could keep these struggles private even as companies, dealers, and other actors profited from the surrounding system.

Support was not yet easy to find online. In 2012 there were no Facebook groups connecting distressed parents across the state to exchange information about rehabilitation, coping, or practical and financial help. Robin Roth experienced her son’s death as a source of personal shame and carried anger toward the young man she held responsible. Her experience illustrates how addiction and loss could be interpreted within families as parental failure, intensifying isolation rather than creating a shared route to assistance.

Stigma also affected whether treatment counted as recovery in the eyes of peers. During the months Tess attended Narcotics Anonymous meetings, she was uncomfortable and distracted, and she remembered being stigmatized in earlier twelve-step settings for taking buprenorphine. Although Narcotics Anonymous officially accepted medication-assisted treatment, members asked to sponsor or mentor her declined. That gap between formal policy and individual practice left her without the peer support she had sought. The rejection reflected a wider divide between public-health approaches that recognized medication and recovery cultures that could regard it as merely substituting one opioid for another.

A Condition Framed by Unequal Outcomes

The book’s figures and episodes resist reducing opioid use disorder to a single route or a single kind of patient. In 2015, an estimated 2.6 million Americans were already addicted to opioids: two million had prescription opioid-use disorder, and 591,000 were addicted to heroin. The distinction in those figures also sits alongside the book’s account of movement between prescription opioids and heroin, and of communities where prescribing, dependence, and treatment access were shaped by local circumstances.

Treatment itself could be difficult to sustain. The cited evidence reports that half of buprenorphine patients leave treatment within six months, and that poor outcomes often follow dropout. This does not make medication ineffective; it underscores how much depends on continuing care and support. The book repeatedly contrasts the promise of a treatment with the practical conditions required to receive it: cost, eligibility, the length of a program, family resources, and whether a recovery community welcomes a person using medication.

By placing medical promotion, family testimony, and treatment barriers in the same account, the book presents opioid use disorder as more than a diagnosis or a private crisis. The condition takes shape in encounters among patients, clinicians, pharmaceutical companies, families, peer groups, and institutions. Its consequences are personal, but the opportunities for prevention and recovery are structured by decisions far beyond the individual patient.